Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk - Top-Institutions - MDSpire

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk

  • By

  • Sailish Honap

  • Marc Debouverie

  • Massimo Filippi

  • Daniel Selchen

  • Vipul Jairath

  • Silvio Danese

  • Laurent Peyrin-Biroulet

  • November 29, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Neurology
    • Immunology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Neurology
    • Neuroimmunology

  • #3

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Neurology
    • Immunology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Neurology
    • Clinical Research

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Neurology
    • Immunology

Original Source(s)

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk

  • by Sailish Honap, Marc Debouverie, Massimo Filippi, Daniel Selchen, Vipul Jairath, Silvio Danese, Laurent Peyrin-Biroulet

  • November 29, 2025

Related Content

Melatonin-induced restoration of the intestinal mucosal barrier in inflammatory bowel disease via activation of the SIRT1-LKB1-pAMPK axis

The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn’s disease

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min